ASTELLAS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASTELLAS, and what generic alternatives to ASTELLAS drugs are available?
ASTELLAS has thirty-seven approved drugs.
There are thirty US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are four hundred and thirty-five patent family members on ASTELLAS drugs in forty-two countries and sixty-five supplementary protection certificates in nineteen countries.
Summary for ASTELLAS
International Patents: | 435 |
US Patents: | 30 |
Tradenames: | 21 |
Ingredients: | 16 |
NDAs: | 37 |
Patent Litigation for ASTELLAS: | See patent lawsuits for ASTELLAS |
Drugs and US Patents for ASTELLAS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | ARISTOCORT A | triamcinolone acetonide | CREAM;TOPICAL | 088819-001 | Oct 16, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Astellas | XOSPATA | gilteritinib fumarate | TABLET;ORAL | 211349-001 | Nov 28, 2018 | RX | Yes | Yes | 10,786,500 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astellas | CRESEMBA | isavuconazonium sulfate | POWDER;INTRAVENOUS | 207501-001 | Mar 6, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-002 | Nov 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ASTELLAS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,582,617 | ⤷ Sign Up |
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 8,470,801 | ⤷ Sign Up |
Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | 6,576,259 | ⤷ Sign Up |
Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-001 | Mar 6, 2015 | 7,459,561 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
International Patents for ASTELLAS Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 101878888 | ⤷ Sign Up |
China | 101155822 | ⤷ Sign Up |
China | 101460467 | ⤷ Sign Up |
Brazil | 112016000546 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ASTELLAS Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2428508 | CR 2020 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: GILTERITINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/19/1399 20191028 |
1893196 | C300632 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/846 20130621 |
2428508 | 132020000000016 | Italy | ⤷ Sign Up | PRODUCT NAME: GILTERITINIB E SUOI SALI(XOSPATA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1399, 20191028 |
1893196 | CA 2013 00065 | Denmark | ⤷ Sign Up | PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.